.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FA01_Rituximab.Rituximab .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01F_MonoclonalAntibodiesAndAntibodyDrugConjugates.L01FA01_Rituximab.Rituximab| name: | Rituximab |
| ATC code: | L01FA01 | route: | intravenous |
| n-compartments | 2 |
Rituximab is a chimeric monoclonal antibody directed against the CD20 antigen found on the surface of B lymphocytes. It is primarily used in the treatment of B-cell non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and various autoimmune diseases such as rheumatoid arthritis and granulomatosis with polyangiitis. Rituximab is approved and widely used in clinical practice today.
Pharmacokinetic parameters in adult patients with B-cell non-Hodgkin's lymphoma following intravenous administration. Parameters derived from a two-compartment model with first-order elimination.
Gota, V, et al., & Menon, H (2016). Population pharmacokinetics of Reditux™, a biosimilar Rituximab, in diffuse large B-cell lymphoma. Cancer chemotherapy and pharmacology 78(2) 353–359. DOI:10.1007/s00280-016-3083-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/27329361
Gibiansky, E, et al., & Jamois, C (2021). Population pharmacokinetic and exposure-response analyses of intravenous and subcutaneous rituximab in patients with chronic lymphocytic leukemia. CPT: pharmacometrics & systems pharmacology 10(8) 914–927. DOI:10.1002/psp4.12665 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34110098
Cohen, SB, et al., & Totoritis, MC (2006). Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis and rheumatism 54(9) 2793–2806. DOI:10.1002/art.22025 PUBMED:https://pubmed.ncbi.nlm.nih.gov/16947627